MET and glioblastoma: A recent phase Ib clinical study reported a favorable safety profile and efficacy of multimodal GBM therapy with crizotinib, TMZ, and radiotherapy, supporting the feasibility of incorporating c-MET inhibitors into the current GBM treatment regime 52.